Neuropathology markers and pathways associated with molecular targets for antipsychotic drugs in postmortem brain tissues: Exploration of drug targets through the Stanley Neuropathology Integrative Database

European Neuropsychopharmacology

Volumn 22, Issue 10, 2012, Pages 683-694

  Kim, Sanghyeon ^a   Zavitsanou, Katerina ^b,c,d   Gurguis, George ^e,f   Webster, Maree J ^a  

^a Stanley Medical Research Institute   (United States)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

^d Schizophrenia Research Institute   (Australia)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

Author keywords

BDNF; Mechanisms; Myelination; Neurotransmitter receptors; Schizophrenia; SNCID

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; BRAIN DERIVED GROWTH FACTOR; DOPAMINE 2 RECEPTOR; MESSENGER RNA; METABOTROPIC RECEPTOR 2; MUSCARINIC M1 RECEPTOR; MUSCARINIC M4 RECEPTOR; NEUROLEPTIC AGENT; SEROTONIN RECEPTOR;

APOPTOSIS; ARTICLE; BRAIN FUNCTION; BRAIN REGION; BRAIN TISSUE; COMPUTER PROGRAM; CORRELATION ANALYSIS; DATA BASE; DRUG TARGETING; FRONTAL CORTEX; HIPPOCAMPUS; HUMAN; IMMUNE RESPONSE; INFLAMMATION; METABOLISM; MYELINATION; NEUROPATHOLOGY; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN FUNCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STANLEY NEUROPATHOLOGY INTEGRATIVE DATABASE;

ANTIPSYCHOTIC AGENTS; BIOLOGICAL MARKERS; BIPOLAR DISORDER; BRAIN-DERIVED NEUROTROPHIC FACTOR; DATA MINING; DATABASES, FACTUAL; DEPRESSIVE DISORDER, MAJOR; FEMALE; FRONTAL LOBE; GENE EXPRESSION REGULATION; HIPPOCAMPUS; HUMANS; MALE; MOLECULAR TARGETED THERAPY; MYELIN SHEATH; NERVE TISSUE PROTEINS; NEURONS; RECEPTORS, ADRENERGIC, ALPHA-2; RECEPTORS, DOPAMINE D2; RECEPTORS, METABOTROPIC GLUTAMATE; RNA, MESSENGER; SCHIZOPHRENIA;

EID: 84865532845     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2012.01.010     Document Type: Article

References (62)

1. Agid O., Seeman P., Kapur S. The "delayed onset" of antipsychotic action-an idea whose time has come and gone. J. Psychiatry Neurosci. 2006, 31:93-100.
2. Angelucci F., Brene S., Mathe A.A. BDNF in schizophrenia, depression and corresponding animal models. Mol. Psychiatry 2005, 10:345-352.
3. Arnsten A.F., Steere J.C., Hunt R.D. The contribution of alpha 2-noradrenergic mechanisms of prefrontal cortical cognitive function. Potential significance for attention-deficit hyperactivity disorder. Arch. Gen. Psychiatry 1996, 53:448-455.
4. Aten J.E., Fuller T.F., Lusis A.J., Horvath S. Using genetic markers to orient the edges in quantitative trait networks: the NEO software. BMC Syst. Biol. 2008, 2:34.
5. Bai O., Chlan-Fourney J., Bowen R., Keegan D., Li X.M. Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs. J. Neurosci. Res. 2003, 71:127-131.
6. Bender R., Lange S. Adjusting for multiple testing-when and how?. J. Clin. Epidemiol. 2001, 54:343-349.
7. Bessho Y., Nakanishi S., Nawa H. Glutamate receptor agonists enhance the expression of BDNF mRNA in cultured cerebellar granule cells. Brain Res. Mol. Brain Res. 1993, 18:201-208.
8. Boulanger L.M. Immune proteins in brain development and synaptic plasticity. Neuron 2009, 64:93-109.
9. Bozzi Y., Borrelli E. Absence of the dopamine D2 receptor leads to a decreased expression of GDNF and NT-4 mRNAs in restricted brain areas. Eur. J. Neurosci. 1999, 11:1275-1284.
10. Brown A.S., Derkits E.J. Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. Am. J. Psychiatry 2010, 167:261-280.
11. Burnet P.W., Chen C.P., McGowan S., Franklin M., Harrison P.J. The effects of clozapine and haloperidol on serotonin-1A, -2A and -2C receptor gene expression and serotonin metabolism in the rat forebrain. Neuroscience 1996, 73:531-540.
12. Cassidy F., Forest K., Murry E., Carroll B.J. A factor analysis of the signs and symptoms of mania. Arch. Gen. Psychiatry 1998, 55:27-32.
13. Chlan-Fourney J., Ashe P., Nylen K., Juorio A.V., Li X.M. Differential regulation of hippocampal BDNF mRNA by typical and atypical antipsychotic administration. Brain Res. 2002, 954:11-20.
14. Ferno J., Raeder M.B., Vik-Mo A.O., Skrede S., Glambek M., Tronstad K.J., Breilid H., Lovlie R., Berge R.K., Stansberg C., Steen V.M. Antipsychotic drugs activate SREBP-regulated expression of lipid biosynthetic genes in cultured human glioma cells: a novel mechanism of action?. Pharmacogenomics J. 2005, 5:298-304.
15. Galea I., Bechmann I., Perry V.H. What is immune privilege (not)?. Trends Immunol. 2007, 28:12-18.
16. Girgenti M.J., Nisenbaum L.K., Bymaster F., Terwilliger R., Duman R.S., Newton S.S. Antipsychotic-induced gene regulation in multiple brain regions. J. Neurochem. 2010, 113:175-187.
17. Gray J.A., Roth B.L. The pipeline and future of drug development in schizophrenia. Mol. Psychiatry 2007, 12:904-922.
18. Gry M., Rimini R., Stromberg S., Asplund A., Ponten F., Uhlen M., Nilsson P. Correlations between RNA and protein expression profiles in 23 human cell lines. BMC Genomics 2009, 10:365.
19. Guillin O., Diaz J., Carroll P., Griffon N., Schwartz J.C., Sokoloff P. BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization. Nature 2001, 411:86-89.
20. Gygi S.P., Rochon Y., Franza B.R., Aebersold R. Correlation between protein and mRNA abundance in yeast. Mol. Cell. Biol. 1999, 19:1720-1730.
21. Hakak Y., Walker J.R., Li C., Wong W.H., Davis K.L., Buxbaum J.D., Haroutunian V., Fienberg A.A. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:4746-4751.
22. Hashimoto K., Shimizu E., Iyo M. Critical role of brain-derived neurotrophic factor in mood disorders. Brain Res. Brain Res. Rev. 2004, 45:104-114.
23. Huang E.J., Reichardt L.F. Neurotrophins: roles in neuronal development and function. Annu. Rev. Neurosci. 2001, 24:677-736.
24. Hyman C., Juhasz M., Jackson C., Wright P., Ip N.Y., Lindsay R.M. Overlapping and distinct actions of the neurotrophins BDNF, NT-3, and NT-4/5 on cultured dopaminergic and GABAergic neurons of the ventral mesencephalon. J. Neurosci. 1994, 14:335-347.
25. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13:261-276.
26. Kim S., Webster M.J. Integrative genome-wide association analysis of cytoarchitectural abnormalities in the prefrontal cortex of psychiatric disorders. Mol. Psychiatry 2010, 16:452-461.
27. Kim S., Webster M.J. The Stanley neuropathology consortium integrative database: a novel, web-based tool for exploring neuropathological markers in psychiatric disorders and the biological processes associated with abnormalities of those markers. Neuropsychopharmacology 2010, 35:473-482.
28. Leucht S., Corves C., Arbter D., Engel R.R., Li C., Davis J.M. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009, 373:31-41.
29. Lipska B.K., Khaing Z.Z., Weickert C.S., Weinberger D.R. BDNF mRNA expression in rat hippocampus and prefrontal cortex: effects of neonatal ventral hippocampal damage and antipsychotic drugs. Eur. J. Neurosci. 2001, 14:135-144.
30. Lopez-Figueroa A.L., Norton C.S., Lopez-Figueroa M.O., Armellini-Dodel D., Burke S., Akil H., Lopez J.F., Watson S.J. Serotonin 5-HT1A, 5-HT1B, and 5-HT2A receptor mRNA expression in subjects with major depression, bipolar disorder, and schizophrenia. Biol. Psychiatry 2004, 55:225-233.
31. Marazziti D., Giannaccini G., Giromella A., Betti L., Pesce D., Nardi I., Rossi A., Lucacchini A., Cassano G.B. [3H]-ketanserin binding sites in different psychiatric disorders. Neurochem. Int. 2003, 42:511-516.
32. McAllister A.K., van de Water J. Breaking boundaries in neural-immune interactions. Neuron 2009, 64:9-12.
33. Moghaddam B., Adams B.W. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 1998, 281:1349-1352.
34. Mueser K.T., McGurk S.R. Schizophrenia. Lancet 2004, 363:2063-2072.
35. Nasrallah H.A. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol. Psychiatry 2008, 13:27-35.
36. Patil S.T., Zhang L., Martenyi F., Lowe S.L., Jackson K.A., Andreev B.V., Avedisova A.S., Bardenstein L.M., Gurovich I.Y., Morozova M.A., Mosolov S.N., Neznanov N.G., Reznik A.M., Smulevich A.B., Tochilov V.A., Johnson B.G., Monn J.A., Schoepp D.D. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat. Med. 2007, 13:1102-1107.
37. Polesskaya O.O., Sokolov B.P. Differential expression of the "C" and "T" alleles of the 5-HT2A receptor gene in the temporal cortex of normal individuals and schizophrenics. J. Neurosci. Res. 2002, 67:812-822.
38. Poo M.M. Neurotrophins as synaptic modulators. Nat. Rev. Neurosci. 2001, 2:24-32.
39. Purcell S., Neale B., Todd-Brown K., Thomas L., Ferreira M.A., Bender D., Maller J., Sklar P., de Bakker P.I., Daly M.J., Sham P.C. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 2007, 81:559-575.
40. Ryan M.M., Lockstone H.E., Huffaker S.J., Wayland M.T., Webster M.J., Bahn S. Gene expression analysis of bipolar disorder reveals downregulation of the ubiquitin cycle and alterations in synaptic genes. Mol. Psychiatry 2006, 11:965-978.
41. Saetre P., Emilsson L., Axelsson E., Kreuger J., Lindholm E., Jazin E. Inflammation-related genes up-regulated in schizophrenia brains. BMC Psychiatry 2007, 7:46.
42. Sartorius L.J., Weinberger D.R., Hyde T.M., Harrison P.J., Kleinman J.E., Lipska B.K. Expression of a GRM3 splice variant is increased in the dorsolateral prefrontal cortex of individuals carrying a schizophrenia risk SNP. Neuropsychopharmacology 2008, 33:2626-2634.
43. Schmitt A., Leonardi-Essmann F., Durrenberger P.F., Parlapani E., Schneider-Axmann T., Spanagel R., Arzberger T., Kretzschmar H., Herrera-Marschitz M., Gruber O., Reynolds R., Falkai P., Gebicke-Haerter P.J. Regulation of immune-modulatory genes in left superior temporal cortex of schizophrenia patients: a genome-wide microarray study. World J. Biol. Psychiatry 2011, 12:201-215.
44. Seeman P., Lee T., Chau-Wong M., Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976, 261:717-719.
45. Shao L., Vawter M.P. Shared gene expression alterations in schizophrenia and bipolar disorder. Biol. Psychiatry 2008, 64:89-97.
46. Shekhar A., Potter W.Z., Lightfoot J., Lienemann J., Dube S., Mallinckrodt C., Bymaster F.P., McKinzie D.L., Felder C.C. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am. J. Psychiatry 2008, 165:1033-1039.
47. Shelton R.C., Claiborne J., Sidoryk-Wegrzynowicz M., Reddy R., Aschner M., Lewis D.A., Mirnics K. Altered expression of genes involved in inflammation and apoptosis in frontal cortex in major depression. Mol. Psychiatry 2011, 16:751-762.
48. Shen R.Y., Altar C.A., Chiodo L.A. Brain-derived neurotrophic factor increases the electrical activity of pars compacta dopamine neurons in vivo. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:8920-8924.
49. Siuciak J.A., Clark M.S., Rind H.B., Whittemore S.R., Russo A.F. BDNF induction of tryptophan hydroxylase mRNA levels in the rat brain. J. Neurosci. Res. 1998, 52:149-158.
50. Tkachev D., Mimmack M.L., Ryan M.M., Wayland M., Freeman T., Jones P.B., Starkey M., Webster M.J., Yolken R.H., Bahn S. Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet 2003, 362:798-805.
51. Torrey E.F., Miller J., Rawlings R., Yolken R.H. Seasonality of births in schizophrenia and bipolar disorder: a review of the literature. Schizophr. Res. 1997, 28:1-38.
52. Torrey E.F., Webster M., Knable M., Johnston N., Yolken R.H. The Stanley foundation brain collection and neuropathology consortium. Schizophr. Res. 2000, 44:151-155.
53. Torrey E.F., Bartko J.J., Lun Z.R., Yolken R.H. Antibodies to Toxoplasma gondii in patients with schizophrenia: a meta-analysis. Schizophr. Bull. 2007, 33:729-736.
54. Vaidya V.A., Terwilliger R.M., Duman R.S. Role of 5-HT2A receptors in the stress-induced down-regulation of brain-derived neurotrophic factor expression in rat hippocampus. Neurosci. Lett. 1999, 262:1-4.
55. van Os J., Kapur S. Schizophrenia. Lancet 2009, 374:635-645.
56. Weickert C.S., Hyde T.M., Lipska B.K., Herman M.M., Weinberger D.R., Kleinman J.E. Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia. Mol. Psychiatry 2003, 8:592-610.
57. Weickert C.S., Ligons D.L., Romanczyk T., Ungaro G., Hyde T.M., Herman M.M., Weinberger D.R., Kleinman J.E. Reductions in neurotrophin receptor mRNAs in the prefrontal cortex of patients with schizophrenia. Mol. Psychiatry 2005, 10:637-650.
58. Weiner D.M., Burstein E.S., Nash N., Croston G.E., Currier E.A., Vanover K.E., Harvey S.C., Donohue E., Hansen H.C., Andersson C.M., Spalding T.A., Gibson D.F., Krebs-Thomson K., Powell S.B., Geyer M.A., Hacksell U., Brann M.R. 5-Hydroxytryptamine2a receptor inverse agonists as antipsychotics. J. Pharmacol. Exp. Ther. 2001, 299:268-276.
59. Wong J., Hyde T.M., Cassano H.L., Deep-Soboslay A., Kleinman J.E., Weickert C.S. Promoter specific alterations of BDNF mRNA in schizophrenia. Neuroscience 2010, 169:1071-1084.
60. Xiao L., Xu H., Zhang Y., Wei Z., He J., Jiang W., Li X., Dyck L.E., Devon R.M., Deng Y., Li X.M. Quetiapine facilitates oligodendrocyte development and prevents mice from myelin breakdown and behavioral changes. Mol. Psychiatry 2008, 13:697-708.
61. Zavitsanou K., Katsifis A., Mattner F., Huang X.F. Investigation of m1/m4 muscarinic receptors in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression disorder. Neuropsychopharmacology 2004, 29:619-625.
62. Zipursky R.B., Meyer J.H., Verhoeff N.P. PET and SPECT imaging in psychiatric disorders. Can. J. Psychiatry 2007, 52:146-157.